LOGIN  |  REGISTER
Viking Therapeutics
Viking Therapeutics

Ensign Increases Operations in Arizona

December 02, 2025 | Last Trade: US$178.99 2.16 -1.19

SAN JUAN CAPISTRANO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the operations of “Santa Rosa Care Center”, a 144-bed skilled nursing facility located in Tucson, Arizona which is subject to a long-term, triple net lease with a third-party landlord. This acquisition was effective as of December 1, 2025.

“We are excited to add another operation to one of our more mature and thriving markets,” said Barry Port, Ensign’s Chief Executive Officer. “This facility clusters well with other operations in Tucson and we are looking forward to seeing what the future holds,” he continued.

Christie Jones, market leader for Bandera Healthcare LLC, Ensign’s Arizona-based subsidiary, added, “We are excited to work together with the outstanding care team at the facility and combine their expertise with Ensign’s quality of service to provide our residents and their families the care they want and need.”

In a separate transaction on the same day, Ensign announced that it acquired the real estate and operations of “Willow Point Rehabilitation and Nursing Center”, a 45-bed skilled nursing facility located in Kansas City, Kansas. The real estate was purchased by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign’s captive real estate company, and operations were leased to an Ensign-affiliated operator, subject to a long-term lease effective as of December 1, 2025.

In another transaction on the same day, Ensign announced that it acquired the operations to two facilities in Colorado (i) “The Rehabilitation Center at Sandalwood”, a 103-bed skilled nursing facility located in Wheat Ridge, Colorado, and (ii) “Edgewater Health and Rehabilitation”, a 69-bed skilled nursing facility located in Lakewood, Colorado. Both facilities are operated by an Ensign affiliated operator and are subject to a long-term triple net lease. This acquisition was effective as of December 1, 2025.

These acquisitions bring Ensign’s growing portfolio to 373 healthcare operations, which includes 47 senior living operations, across 17 states. Ensign subsidiaries, including Standard Bearer, own 156 real estate assets. Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, senior living and other healthcare related businesses throughout the United States.

About Ensign™

The Ensign Group, Inc.’s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 373 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information

The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Last Trade: US$178.99
Daily Change: -2.16 -1.19
Daily Volume: 262,880
Market Cap: US$10.370B

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page